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ABSTRACT  
 
Objective: To examine the effect of chronic hypertension (CH), with and without 
superimposed preeclampsia (PE), on the incidence of small for gestational age (SGA) 
neonates, and explore possible mechanisms for such association. 
 
Methods: The data for the study were derived from prospective screening for adverse 
pregnancy outcomes in women with singleton pregnancies attending for their first routine 
hospital visit at 11-13 weeks’ gestation, which included recording of maternal 
characteristics and medical history and measurement of mean arterial pressure (MAP). 
Birth weight z-score, adjusted for gestational age and for maternal and pregnancy 
characteristics, and incidence of SGA were compared between those with and without 
CH in the total population and in the subgroups with and without PE. Regression 
analysis was used to examine the relationship between MAP and birth weight z-score 
and incidence of SGA and PE in those with and without CH. 
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
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Results: The study population constituted 74,226 pregnancies, including 1,052 (1.4%) 
with CH and 73,174 without CH. Preeclampsia developed in 233 (22.1%) cases of the 
group with CH and in 1,662 (2.3%) of those without CH. In the group that developed PE, 
there was no significant difference between those with CH and those without CH in 
either the median birth weight z-score or the incidence of SGA. In the group without PE, 
the incidence of SGA was twice as high in those with than in those without CH. There 
was a significant association between log10 MAP multiple of the median and incidence of 
SGA and PE which was more marked in those with CH than in those without CH. 
 
Conclusion: CH is associated with increased risk of SGA and PE and this is related to 
MAP at 11-13 weeks’ gestation. 
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Introduction 
 
Chronic hypertension (CH) is found in 1-2% of pregnancies and in such women the 
incidence of small for gestational age (SGA) neonates, after adjustment for potential 
confounding variables from maternal characteristics, medical and obstetric history, is 
twice as high than in women without CH.1 However, it is uncertain whether the observed 
increased risk of SGA in pregnancies with CH is the direct consequence of the disease 
itself and / or its treatment or it is due to the association with a high incidence of 
superimposed preeclampsia (PE), which is >20% in those with CH and only 2% in those 
without CH, and that CH in the absence of PE does not increase the risk of SGA.2  
 
The objective of this study is first, to examine the effect of CH, with and without 
superimposed PE, on birth weight and the incidence of SGA neonates, and second, 
explore possible mechanisms underlying the association between CH and SGA. 
 
 
Methods 
 
Study population  
 
This was a prospective screening study for adverse obstetric outcomes in pregnant 
women attending for their first routine hospital visit at King’s College Hospital, London, 
UK (between March 2006 and July 2015) and Medway Maritime Hospital, Kent, UK 
(between February 2007 and November 2015). This visit, which was held at 11+0-13+6 
weeks’ gestation, included recording of maternal demographic characteristics and 
obstetric and medical history, measurement of maternal weight and height, ultrasound 
examination for the measurement of the fetal crown-rump length (CRL) to determine 
gestational age,3 examination of the fetal anatomy for the diagnosis of major fetal 
defects,4 and recoding of mean arterial pressure (MAP) by validated automated devices 
and standardized protocol.5 
 
Written informed consent was obtained from women who agreed to participate in the 
study, which was approved by the Ethics Committee of each participating Hospital. Data 
on pregnancy outcomes were collected from the hospital maternity records and the 
women’s general medical practitioners. The inclusion criteria for this study were 
singleton pregnancies examined at 11+0-13+6 weeks of gestation, resulting in the live birth 
or stillbirth of non-malformed babies at >24 weeks’ gestation. We excluded pregnancies 
with fetal aneuploidies or major defects diagnosed either prenatally or in the neonatal 
period, pregnancies ending in miscarriage and those ending in termination for 
psychosocial reasons. 
 
Outcome measures 
 
Women were subdivided into those with CH and those without CH based on their 
medical history reported at the 11-13 weeks visit. The diagnosis of PE was made 
according to the guidelines of the International Society for the Study of Hypertension in 
Pregnancy.6 The systolic blood pressure should be >140 mm Hg and/or the diastolic 
blood pressure should be >90 mmHg on at least two occasions four hours apart 
developing after 20 weeks’ gestation in a previously normotensive woman and in 
addition there should be significant proteinuria (>300 mg in 24 hours, or two readings of 
at least ++ on dipstick analysis of midstream or catheter urine specimen, if no 24-hour 
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collection is available). In pregnancies with CH, diagnosis of superimposed PE requires 
the development of significant proteinuria after 20 weeks’ gestation in a previously non 
proteinuric woman.  
 
Birth weight was expressed as a z-score which was calculated as a difference between 
observed and expected birth weight, divided by the fitted standard deviation. The 
expected birth weight was calculated after adjustment for gestational age and maternal 
characteristics from our population of phenotypically normal neonates born alive at >24 
weeks’ gestation.7  
 
Statistical Analysis  
 
Data for continuous variables were expressed as median and interquartile range (IQR). 
Mann-Whitney U-test was used to examine the significance of difference between 
continuous variables and χ2 test or Fisher’s exact test was used for categorical variables. 
 
In pregnancies that developed PE, the relationship between birth weight z-score with 
gestational age at delivery was assessed using regression analysis and slope and 
intercepts of the regression lines were compared for those with CH and those without 
CH. In pregnancies without PE, comparison of median birth weight z-score, adjusted for 
gestational age and for maternal and pregnancy characteristics, between those with and 
without CH was carried out by Mann-Whitney U-test. The proportion of SGA pregnancies 
<5th and <10th percentile was determined in those with and without CH and the 
significance of difference in proportions was examined by χ2 test. Similarly, the 
relationship between MAP, expressed as a multiple of the median (MoM) adjusted for 
maternal characteristics,8 and birth weight z-score was examined using regression 
analysis and the significance of difference between slope and intercepts between the 
two groups was assessed. Comparison of slopes between regression lines in the two 
groups was carried out by introducing interaction terms in the regression analysis and if 
there was no significant difference between slopes in the two groups, then a comparison 
of intercepts of the regression lines was assessed by examining the coefficient [95% 
confidence intervals (CI)] for CH.9,10 Logistic regression analysis was used to estimate 
the risk of delivering an SGA neonate <5th and <10th percentile from MAP MoM values in 
those with CH and those without CH. Similarly, logistic regression analysis was used to 
estimate the risk of delivering with PE from MAP MoM values in those with CH and in 
those without CH. 
 
The statistical software package SPSS Statistics 20.0 (SPSS Inc., Chicago, Ill., USA) 
was used for data analyses. 
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Results 
 
Study population 
 
The study population satisfying the inclusion criteria constituted 74,226 pregnancies, 
including 1,052 (1.4%) with CH and 73,174 without CH. Preeclampsia developed in 233 
(22.1%) cases of the group with CH and in 1,662 (2.3%) of those without CH. Maternal 
characteristics, medical and obstetric history in pregnancies with and without CH are 
compared in Table 1. 
 
Birth weight z-score and incidence of SGA 
 
In the total population, there was a significant difference between those with CH and 
those without CH in both the median birth weight z-score (p<0.0001) and the incidence 
of SGA <5th percentile (12.2% vs. 6.1%; p<0.0001) and <10th percentile (19.4% vs. 
11.5%; p<0.0001; Table 2; Figure 1). Similarly, in the group that did not develop PE, 
there was a significant difference between those with CH and those without CH in both 
the median birth weight z-score (p=0.012) and the incidence of SGA <5th percentile 
(10.3% vs. 5.7%; p<0.0001) and <10th percentile (16.5% vs. 11.1%; p<0.0001; Table 2; 
Figure 1). 
 
In the group that developed PE, there was no significant difference between those with 
CH and those without CH in either the median birth weight z-score (p=0.694) or the 
incidence of SGA <5th percentile (18.9% vs. 20.5%; p=0.576) and <10th percentile 
(29.2% vs. 28.9%; p=0.916). Similarly, there was no significant difference between the 
two groups in either the slope (standard error 0.026, p=0.731) or the intercept (standard 
error 0.088, p=0.184) of the regression lines describing the relationship between birth 
weight z-score and gestational age at delivery with PE (Figure 2). 
 
Relationship between MAP and risk of SGA 
 
There was a significant association between MAP MoM and birth weight z-score in those 
with CH (r=-0.20, p<0.0001) and in those without CH (r=-0.02, p<0.0001) and there was 
a significant difference in the slope (p<0.0001) and intercept (p<0.0001) of the 
regression line between those with and those without CH (Figure 3).  
 
Logistic regression analysis demonstrated that in patients with CH there was a 
significant association between log10 MAP MoM and risk of delivering a SGA neonate 
<5th percentile (y=-2.469 + 7.366 log10 MAP MoM; Nagelkerke R2=0.024, p<0.0001; 
Figure 4) and a SGA neonate <10th percentile (y=-1.852 + 7.727 log10 MAP MoM; 
Nagelkerke R2=0.032, p<0.0001; Figure 4). Similarly, in patients without CH there was a 
significant association between log10 MAP MoM and risk of delivering a SGA neonate 
<5th percentile (y=-2.827 + 2.961 log10 MAP MoM; Nagelkerke R2=0.002, p<0.0001; 
Figure 4) and a SGA neonate <10th percentile (y=-2.084 + 2.151 log10 MAP MoM; 
Nagelkerke R2=0.001, p<0.0001; Figure 4).  
 
Relationship between MAP and risk of PE 
 
Logistic regression analysis demonstrated that in patients with CH there was a 
significant association between log10 MAP MoM and risk of delivering with PE (y=-1.703 
+ 8.144 log10 MAP MoM; Nagelkerke R2=0.037, p<0.0001; Figure 4). Similarly, in 
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patients without CH there was a significant association between log10 MAP MoM and risk 
of delivering with PE (y=-3.919 + 16.784 log10 MAP MoM; Nagelkerke R2=0.044, 
p<0.0001; Figure 4). 
 
 
 
Discussion 
 
Principal findings of this study 
 
The findings of this study demonstrate that in pregnancies with CH, compared to those 
without CH, there is a two-fold increase in incidence of SGA neonates and 10-fold 
increase in the incidence of PE. In pregnancies that did not develop PE the incidence of 
SGA <5th percentile was 10.3% in those with CH and 5.7% in those without CH, whereas 
in pregnancies that developed PE the incidence of SGA was about 20% in both groups. 
Consequently, the increase in SGA in pregnancies with CH is partly due to the 
association of CH with a high incidence of superimposed PE, but it is primarily the 
consequence of the disease itself.  
 
The incidence of SGA and PE in all pregnancies increased with the level of MAP at 11-
13 weeks’ gestation and this increase was particularly marked in women with CH. This 
raises the possibility that higher first trimester maternal blood pressure (BP) directly 
affects placental development and that the threshold for placental damage is significantly 
lowered by CH. 
 
Strengths and limitations 
 
The strengths of this study are first, prospective examination of a large population of 
pregnancies with and without CH, second, use of a standardized protocol for 
measurement of MAP and expression of the values as MoMs after adjustment for factors 
that affect the measurements,5,8 and third, expression of birth weights as z-scores, 
adjusted for gestational age and maternal characteristics.7 Potential limitations are the 
lack of longitudinal BP observations and the relationship of treatment on study 
outcomes. 
 
Comparison with previous studies 
 
The relationship between maternal BP and fetal growth has primarily been examined in 
the context of second or third trimester treatment studies for women with CH or 
gestational hypertension. As a result of these studies, the American College of 
Obstetricians and Gynecologists (ACOG) recommends that patients with CH should 
receive antihypertensive medication only if the disease is severe with systolic blood 
pressure (BP) of >160 mm Hg or diastolic BP of >110 mm Hg, but not if the disease is 
mild to moderate with systolic BP of 140-159 mm Hg or diastolic BP of 90-109 mm Hg.11 
Similarly, in the UK, the National Institute for Health and Clinical Excellence (NICE) 
guideline recommends the use of antihypertensive drugs only when the BP is greater 
than 150/100 mm Hg.12 The basis for the reluctance to recommend therapy in mild to 
moderate disease is that reduction in BP or the drugs themselves may have an adverse 
effect on fetal growth with an estimated decrease in birth weight by 145 g for every 10 
mm decrease in MAP.13,14 However, in these meta-analyses most patients had 
gestational hypertension, rather than CH and in most studies therapy was initiated in the 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
late second or early third trimester. A recent Cochrane review of all randomised trials 
evaluating any antihypertensive drug treatment for mild to moderate hypertension during 
pregnancy reported that therapy was associated with halving in the risk of developing 
severe hypertension, but there was no significant effect on the risk of PE or SGA.15 A 
multicenter trial involving 987 women at a median gestational age of 24 (range 14-33) 
weeks, with CH or gestational hypertension and diastolic BP of 90-105 mm Hg, 
compared a policy of tight control in BP with a target diastolic BP of  85 mm Hg with a 
policy of less-tight control with target diastolic BP of 100 mm Hg; development of severe 
hypertension was lower in the tight-control group but there was no significant difference 
between the two policies in incidence of PE or SGA.16 
 
A secondary analysis of a randomized trial on low-dose aspirin for prevention of PE in 
high-risk women enrolled at a median gestational age of 19 weeks,17 examined the 
relation of pre-enrolment BP with pregnancy outcome in 759 women with CH.18 The rate 
of SGA <10th percentile increased from 9% for those with pre-enrolment BP <140/90 mm 
Hg to 12% for BP140–150/90–99 mm Hg and 24% for BP 151–159/100–109 mm Hg; 
similarly, there was an increase in the incidence of superimposed PE from 21% to 30% 
and 42%, respectively.18 
 
Clinical implications of the study 
 
In CH there is remodeling of small arterial resistance vessels leading to relative 
thickening of the muscular media, vasoconstriction and decreased capacity for 
vasodilation.19-22 In the first trimester of pregnancy trophoblast invasion is not yet 
complete and the maternal uterine arteries still possess a muscular wall that is 
potentially susceptible to the adverse effects of high BP. It could be postulated that, in 
the presence of such impaired placental vasculature, maintenance of normal intervillous 
oxygenation necessitate a relatively high perfusion pressure during the second and third 
trimesters; consequently, lowering the BP during this time may have an adverse effect on 
fetal growth13,14 or at least not decrease the high rates in PE and SGA observed in 
pregnancies with CH.15,16 
 
The extent to which in CH normalization of BP in the first trimester could improve 
placentation and prevent PE and SGA remains to be determined. 
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Figure legends 
 
Figure 1. Box and whisker plots of birth weight z-score in those with CH (black box) and 
those without CH (white box) in the total population (left) and in the group that did not 
develop PE (right). 
 
Figure 2. Individual points and regression lines describing the relationship between birth 
weight z-score and gestational age at delivery with PE in patients with CH (red dots and 
line) and those without CH (black dots and line). 
 
Figure 3. Association between MAP MoM and birth weight z-score in pregnancies with 
CH (red dots and regression line) and in those without CH (black dots and black 
regression line).  
 
Figure 4. Relationship of MAP MoM with risk of delivering a SGA neonate (left) or 
developing PE (right) in pregnancies with CH (red lines) and in those without CH (black 
lines).  
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Table 1. Maternal characteristics, medical and obstetric history in pregnancies with and without 
chronic hypertension  
 
Maternal characteristics Chronic hypertension (n=1,052) 
No chronic hypertension 
(n=73,174) 
GA at recruitment (weeks), median (IQR) 12.7 (12.3 – 13.1) 12.7 (12.3-13.1) 
Age (years), median (IQR) 34.5 (30.7 – 38.3)** 30.9 (26.4 – 34.7) 
Weight (kg), median (IQR) 82.0 (69.0 – 95.4)** 67.0 (59.2 – 77.3) 
Height (cm), median (IQR) 164.4 (160.0 – 168.2) 164.2 (160.0 – 168.9) 
Racial origin   
     Caucasian, n (%) 511 (48.6) 53,637 (73.3) 
     Afro-Caribbean, n (%) 470 (44.7)** 13,135 (18.0) 
     South Asian, n (%) 43 (4.1) 3,091 (4.2) 
     East Asian, n (%) 11 (1.0)* 1,415 (1.9) 
     Mixed, n (%) 17 (1.6) 1,896 (2.6) 
Method of conception   
     Spontaneous, n (%) 1,014 (96.4) 70,945 (97.0) 
     Ovulation drugs, n (%) 14 (1.3) 759 (1.0) 
     In vitro fertilization, n (%) 24 (2.3) 1,470 (2.0) 
Cigarette smoking, n (%) 75 (7.1)** 7,438 (10.2) 
History of SLE / APS, n (%) 11 (1.0)** 134 (0.2) 
History of diabetes mellitus   
     Type I, n (%) 15 (1.4)** 290 (0.4) 
     Type II, n (%) 50 (4.8)** 347 (0.5) 
Family history of preeclampsia, n (%) 104 (9.9)** 2,877 (3.9) 
Family history of diabetes mellitus   
     First degree, n (%) 207 (19.7)** 8,923 (12.2) 
     Second degree, n (%) 73 (6.9) 6,261 (8.6) 
Obstetric history   
     Nulliparous, n (%) 334 (31.7) 34,998 (47.8) 
     Previous preeclampsia, n (%) 237 (22.5)** 2,189 (3.0) 
     Previous SGA <10th, n (%) 130 (12.4)** 4,465 (6.1) 
 
  
GA = gestational age; IQR = interquartile range; SLE = systemic lupus erythematosus; APS = 
antiphospholipid syndrome; SGA = birth weight <10th percentile. 
 
*p<0.05 
**p<0.01  
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Table 2. Birth weight z-score and incidence of small for gestational age neonates in 
pregnancies with and without chronic hypertension 
 
Group N 
Birth weight z-score Incidence of small for gestational age 
Median (IQR) p <5th percentile p <10th percentile p 
Total group        
No CH 73,174 0.001 (-0.681 to 0.717)  4,443 (6.1%)  8,394 (11.5%)  
CH 1,052 -0.109 (-0.991 to 0.570) <0.0001 128 (12.2%) <0.0001 203 (19.4%) <0.0001 
        
No PE group        
No CH 71,512 0.010 (-0.667 to 0.721)  4,102 (5.7%)  7,913 (11.1%)  
CH 819 -0.022 (-0.834 to 0.621) 0.012 84 (10.3%) <0.0001 135 (16.5%) <0.0001 
        
PE group        
No CH 1,662 -0.452 (-1.366 to 0.444)  341 (20.5%)  481 (28.9%)  
CH 233 -0.577 (-1.415 to 0.357) 0.694 44 (18.9%) 0.576 68 (29.2%) 0.916 
 
CH = chronic hypertension; PE = preeclampsia; IQR = interquartile range  
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